Novavax

Novavax is a biotechnology company committed to promoting the improvement of global health by discovering, developing, and commercializing innovative vaccines for the prevention of serious infectious diseases. The company's proprietary recombinant technology platform leverages the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles to address urgent global health needs. Novavax's COVID-19 vaccine has been authorized by multiple regulatory agencies worldwide, including the U.S. Food and Drug Administration, the European Commission, and the World Health Organization. The vaccine is currently under review by several regulatory bodies globally for other indications and populations, such as adolescents and as a booster shot. In addition to its COVID-19 vaccine, Novavax is currently conducting a Phase 1/2 clinical trial to evaluate its combined coronavirus-influenza vaccine (CIC), an investigational quadrivalent influenza candidate vaccine, a vaccine based on the Omicron strain (NVX-CoV2515), and a bivalent vaccine based on both the Omicron and original strains. These vaccine candidates all contain Novavax’s proprietary saponin-based Matrix-M adjuvant to enhance immune response and stimulate high levels of neutralizing antibodies.